Cellectar shares surge 13.36% after hours on FDA rare disease designation for iopofosine I-131 and clinical progress.

Cellectar Biosciences, Inc. (CLRB) surged 13.36% in after-hours trading following the announcement of significant regulatory and clinical advancements. The stock’s sharp rise was driven by the U.S. FDA granting iopofosine I-131 the Rare Pediatric Disease Designation for treating inoperable, recurrent, or refractory high-grade pediatric gliomas, a critical milestone for the drug’s development. Additionally, interim Phase 1b trial data for CLOVER-2 showed promising outcomes, including a median progression-free survival of 5.4 months and overall survival of 8.6 months in patients receiving the minimum total dose. Concurrently, preclinical results for CLR 121225, an actinium-based radiopharmaceutical candidate, demonstrated tumor growth inhibition in pancreatic cancer models, signaling pipeline expansion. These developments reinforced investor confidence in Cellectar’s therapeutic pipeline and its positioning in the radiopharmaceutical sector, catalyzing the post-market rally.